paclitaxel albumin-bound

Paclitaxel albumin-bound (nab-paclitaxel) is a nanoparticle formulation of the taxane chemotherapy agent paclitaxel, where the drug is non-covalently bound to human serum albumin. This formulation, specifically the one developed by CSPC OUYI Pharmaceutical (marketed as Keaili in China), is designed to be bioequivalent to the reference product Abraxane. By utilizing albumin as a carrier, the drug avoids the need for solvent-based vehicles like Cremophor EL, thereby reducing the risk of severe hypersensitivity reactions and eliminating the requirement for corticosteroid premedication. The mechanism of action involves the stabilization of microtubules by binding to tubulin, which inhibits their disassembly and disrupts the mitotic spindle, leading to cell cycle arrest and apoptosis. Additionally, the albumin-bound delivery system facilitates enhanced tumor accumulation through gp60-mediated transcytosis and binding to SPARC (Secreted Protein Acidic and Rich in Cysteine) in the tumor microenvironment. It is currently being evaluated in Phase 2 clinical trials, often in combination with carboplatin, for the treatment of platinum-sensitive recurrent ovarian, fallopian tube, and peritoneal cancers.

Brand names

KeailiAbraxane

Other names

nab-paclitaxelnanoparticle albumin-bound paclitaxelalbumin-bound paclitaxel